Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

The market is pricing this as a simple leader-loser story, but the more important second-order effect is margin structure. LLY’s superior execution has likely pulled forward peak enthusiasm and left its multiple vulnerable to even modest slowing, while NVO’s reset creates optionality if the oral GLP-1 franchise broadens the addressable market beyond injection-adverse patients. In other words, the trade is not “who wins obesity,” but “whose cash flow trajectory is most mispriced over the next 12-24 months.”

The near-term risk for NVO is not product failure, but revenue optics: price concessions and mix shift can suppress top-line growth even as prescriptions accelerate. That creates a classic setup where the stock can stay cheap longer than fundamentals deteriorate, but the asymmetry improves if management can show that pill adoption is incremental rather than cannibalistic. For LLY, the main vulnerability is valuation compression if obesity growth normalizes from hyper-growth to merely strong growth; at 37x earnings, the stock needs near-perfect quarterly execution to avoid derating.

The consensus likely underestimates how much of NVO’s downside is already in the price. A 10x multiple and 4% yield imply a lot of franchise decay, which may be too pessimistic if the oral launch improves patient funnel conversion and reduces reliance on brittle supply chains. The real contrarian insight is that NVO does not need to retake category leadership to outperform; it only needs to stop losing share at the margin while sentiment mean-reverts. That makes it a better risk-adjusted setup than LLY for investors with a 6-18 month horizon.